Sobi and Apellis report positive top-line results at 48 weeks from the phase 3 PEGASUS study of pegcetacoplan in PNHPRNewsWire • 12/10/20
Apellis and Sobi Report Positive Top-line Results at 48 Weeks from the Phase 3 PEGASUS Study of Pegcetacoplan in PNHGlobeNewsWire • 12/10/20
Apellis Pharmaceuticals to Present at the 2020 Evercore ISI HealthCONx ConferenceGlobeNewsWire • 11/30/20
Sobi and Apellis announce first patient dosed in potentially registrational ALS study of pegcetacoplanPRNewsWire • 11/19/20
Apellis and Sobi Announce First Patient Dosed in Potentially Registrational ALS Study of PegcetacoplanGlobeNewsWire • 11/19/20
Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of PNHGlobeNewsWire • 11/16/20
Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy (GA) at AAO 2020 VirtualGlobeNewsWire • 11/13/20
Apellis to Present New Data Supporting the Efficacy and Safety of Pegcetacoplan in PNH at the American Society of Hematology Annual MeetingGlobeNewsWire • 11/05/20
Apellis and Sobi Enter Collaboration for Global Co-development and Ex-US Commercialization of Systemic Pegcetacoplan in Rare Diseases with Urgent Need for New TreatmentsGlobeNewsWire • 10/27/20
Apellis Announces 18-Month Data from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy (GA)GlobeNewsWire • 10/19/20
Apellis to Present Positive Results from the Phase 2 DISCOVERY Study of Pegcetacoplan in C3 Glomerulopathy (C3G) at ASN Kidney WeekGlobeNewsWire • 10/09/20
Apellis Initiates Registrational Programs of Pegcetacoplan in Patients with C3G / IC-MPGN and ALS, Rare Diseases with High Unmet NeedGlobeNewsWire • 10/05/20
Apellis Announces New Analysis Demonstrating Targeted C3 Therapy Pegcetacoplan Slows Progression of Early Disease in Patients with Geographic Atrophy (GA)GlobeNewsWire • 10/03/20
Apellis Pharmaceuticals to Present at Stifel’s 2020 Immunology and Inflammation Virtual SummitGlobeNewsWire • 09/24/20
Apellis Announces Late-Breaking Presentation of Targeted C3 Therapy Pegcetacoplan in Patients with Geographic Atrophy (GA) at EURETINA 2020GlobeNewsWire • 09/21/20
Why Is Apellis Pharmaceuticals, Inc. (APLS) Down 3.8% Since Last Earnings Report?Zacks Investment Research • 08/30/20
Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA)GlobeNewsWire • 07/07/20
Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)GlobeNewsWire • 07/02/20